Huntington’s disease has no cure, but a combination of medications, physical therapy, nutritional support, and coordinated specialist care can meaningfully manage symptoms and maintain quality of life for years. Treatment targets three main areas: the involuntary movements (chorea), the psychiatric changes, and the gradual loss of physical function that comes with disease progression.
Medications for Involuntary Movements
Chorea, the unpredictable jerking and writhing movements characteristic of Huntington’s, is the symptom with the most targeted drug options. The FDA has approved three medications specifically for chorea in Huntington’s disease, all of which work by reducing the amount of a signaling chemical available to nerve cells involved in movement.
Tetrabenazine was the first to receive approval and remains widely used. It can significantly reduce chorea, but it carries notable side effects: depression, suicidal thoughts, agitation, difficulty sleeping, weight gain, and what patients describe as a “dulling” of personality. Because of the depression risk, doctors monitor mood closely, and the drug is typically avoided in people already experiencing significant depression.
Deutetrabenazine, approved later, is a chemically modified version designed to be taken less frequently and tolerated more easily. Valbenazine received FDA approval in 2023 for chorea in adults with Huntington’s disease, adding a third option. Having multiple drugs in this class means that if one causes intolerable side effects, switching to another is possible. The goal with all three is finding the lowest effective dose that controls chorea without over-sedating or worsening mood.
Managing Psychiatric Symptoms
The psychiatric side of Huntington’s disease often causes as much distress as the movement problems, sometimes more. Depression and anxiety tend to be prominent in earlier stages, while irritability, agitation, and psychosis become more common as the disease advances. A large retrospective study found that depression was listed as a reason for medication in 63% of early-stage patients but dropped to about 32% in later stages. Irritability, by contrast, rose from 3% to nearly 29%, and psychosis went from under 1% to 16%.
This shifting profile means medication strategies change over time. Antidepressants account for about 74% of psychiatric prescriptions in early stages but drop to around 27% in advanced disease, while antipsychotic prescriptions climb from 7% to nearly 39%. Your care team will likely adjust psychiatric medications periodically as symptoms evolve, so regular check-ins about mood, behavior, and thinking patterns matter throughout the course of the illness.
Physical Therapy and Exercise
Structured exercise is one of the most evidence-backed interventions for maintaining function in Huntington’s disease. Clinical guidelines published in the journal Neurology recommend aerobic exercise at moderate intensity, paired with upper and lower body strengthening, three times per week for a minimum of 12 weeks. This combination has been shown to improve fitness and stabilize or even improve motor function. Programs that include core work, progressive home walking, balance drills, and flexibility exercises have all demonstrated benefit.
Balance training deserves special attention because falls are a major source of injury and lost independence. Effective exercises include sit-to-stand transfers, walking over soft surfaces, stair climbing, lunges, standing with eyes closed, and balance reaction drills. These are ideally individualized and supervised, at least initially, because Huntington’s affects each person’s coordination differently.
Gait training, done one-on-one with a physical therapist, can improve walking speed and step length. For people whose walking becomes increasingly unsteady, a rollator walker has shown benefit in improving gait quality. In later stages, specialized wheelchairs with flexible seat-back angles, supported footrests, pelvic belts, and anti-tipping devices help maintain safe, comfortable positioning.
Breathing exercises also play a role. Inspiratory and expiratory muscle training can strengthen the respiratory muscles and improve cough effectiveness, which becomes important as the disease progresses and swallowing coordination declines.
Nutrition and Weight Management
People with Huntington’s disease burn more calories than you might expect. The disease increases metabolic rate through several mechanisms: dysfunction in the brain’s hunger and energy regulation center, expression of the faulty huntingtin protein in tissues throughout the body, and the constant energy expenditure from involuntary movements. Unintentional weight loss is common and associated with worse outcomes.
European Huntington’s Disease Network guidelines recommend 25 to 35 calories per kilogram of body weight per day. For a 150-pound person, that translates to roughly 1,700 to 2,400 calories daily, though individual needs vary based on activity level and disease stage. Calorie-dense foods, frequent meals, and nutritional supplements are often necessary to prevent weight loss. Working with a dietitian familiar with the disease helps keep calorie intake matched to changing needs as movement patterns and swallowing ability shift over time.
Speech and Swallowing Support
Swallowing difficulty is one of the most serious complications of Huntington’s disease because it raises the risk of choking and aspiration pneumonia. Speech-language pathologists use several compensatory strategies that have shown effectiveness in improving airway protection: modifying food and liquid consistency (thickened liquids, softer foods), adjusting head posture during meals, and teaching specific swallowing maneuvers. These strategies help manage the problem, though no rehabilitative technique has been shown to restore overall swallowing function once it declines.
Speech itself also deteriorates as the muscles of the mouth, tongue, and larynx lose coordination. Speech therapy can help maintain intelligibility longer, and augmentative communication devices become useful when speech becomes too difficult to understand.
Building a Care Team
Huntington’s disease affects movement, cognition, behavior, nutrition, and daily functioning all at once, which is why multidisciplinary care produces better outcomes than seeing a single provider. The ideal team includes a neurologist (preferably trained in movement disorders), a psychiatrist or psychologist, a social worker, a genetic counselor, a physical therapist, an occupational therapist, a speech-language pathologist, a dietitian, and a care coordinator to keep everything connected.
In practice, assembling this full team is difficult. A U.S. survey found that more than 69% of Huntington’s disease practices reported difficulty providing social work, genetic counseling, care coordination, and psychological or psychiatric services. Larger, specialized centers tend to offer more comprehensive staffing, routine weight monitoring, and pre-visit screening. If you live far from a specialized center, telehealth visits and periodic travel to a high-volume clinic, combined with local providers for ongoing therapy, can bridge the gap.
Gene Therapy on the Horizon
The most promising development in Huntington’s treatment is a gene therapy called AMT-130, currently in a Phase I/II clinical trial. This one-time treatment introduces new DNA instructions into brain cells that produce a molecule designed to intercept and destroy the RNA message used to build the harmful huntingtin protein. The result is a permanent reduction in how much of the toxic protein cells produce.
Results reported by University College London researchers in 2025 showed that people who received a high dose of AMT-130 experienced 75% less disease progression over 36 months, as measured by a standardized rating scale, compared to a matched group of patients who did not receive the therapy. This is not yet an approved treatment, and the trial is small, but it represents the first time a therapy has appeared to slow the actual course of the disease rather than just manage symptoms.
For people who carry the Huntington’s gene but have not yet developed symptoms, knowing their genetic status may become increasingly important. Clinical trial participation often requires a confirmed genetic test result, and if disease-modifying treatments eventually reach approval, early identification could allow treatment to begin before significant brain changes occur.